Extramedullary relapse and discordant CD19 expression between bone marrow and extramedullary sites in relapsed acute lymphoblastic leukemia after blinatumomab treatmentChristos Demosthenous, Αchilles Anagnostopoulos, Chrysavgi Lalayanni et al.|Current Problems in Cancer|2018Cited by 26
Pre-Emptive Use of Rituximab in Epstein–Barr Virus Reactivation: Incidence, Predictive Factors, Monitoring, and OutcomesApostolia Papalexandri, Ioanna Sakellari, Eleni Gavriilaki et al.|International Journal of Molecular Sciences|2023Cited by 6
Real-World Evidence on Therapeutic Strategies and Treatment-Sequencing in Patients with Chronic Lymphocytic Leukemia: An International Study of Eric, the European Research Initiative on CLLThomas Chatzikonstantinou, Robert J. Kreitman, Elisabetta Albi et al.|Blood|2021Cited by 1
Pre-Emptive Use of Rituximab in Epstein-Barr Virus Reactivation: Incidence, Predictive Factors, Monitoring, and OutcomesApostolia Papalexandri, Αchilles Anagnostopoulos, Eleni Gavriilaki et al.|Blood|2020Cited by 0